Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Q1 2026 Earnings Presentation
10 slides from Viemed Healthcare's earnings presentation, May 5, 2026
Slide 1: Financial Supplement First Quarter 2026
1 Financial Supplement First Quarter 2026 May 5, 2026 NASDAQ: VMD
Slide 2: Disclaimers: Forward Looking Statements
Disclaimers Forward Looking Statements Certain statements contained in this Financial Supplement may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian
Slide 3: Key Themes for Q1 2026
Key Themes for Q1 2026 3 Strong revenue growth across core services, including continued diversification in sleep and maternal health, combined with a more capital-efficient business mix, drove durable free cash flow generation and supported capital return and deleveraging • Revenue increased 28% ye
Slide 4: Financial and Operational Highlights
Financial and Operational Highlights 4 (expressed in thousands of U.S. Dollars, except operational information). (1) Refer to “Adjusted EBITDA" in this presentation for the definition of Adjusted EBITDA and a reconciliation to its most comparable GAAP measure. (2) Vent Patients represents the number
Slide 5: Service, Payor and Revenue Mix
Medicare 41% Medicaid/ MCO 8% Medicare Advantage 21% Commercial 17% Other 13% Medicare 35% Medicaid/ MCO 10% Medicare Advantage 20% Commercial 23% Other 12% Ventilation 47% Oxygen 8% Sleep 20% Airway Clearance 7% Maternal 8% Staffing 8% Other 2% Q1 2026 Rental 68% Sales 32% Ventilation 54% Oxygen 10
Slide 6: Revenue Highlights
Revenue Highlights 6 For the quarter ended 3/31/26 12/31/25 9/30/25 6/30/25 3/31/25 12/31/24 9/30/24 6/30/24 Rental Revenue (expressed in thousands of USD): Ventilators, non-invasive & invasive $35,360 $35,888 $34,883 $33,819 $32,159 $33,173 $31,772 $30,445 Other home medical equipment rentals $16,1
Slide 7: Liquidity Metrics
Liquidity Metrics 7 Positioned for growth • The Company maintains a healthy balance sheet with effectively no net debt as of March 31, 2026, providing significant financial flexibility. • As of March 31, 2026, the Company had $46 million in unfunded commitments available under its existing credit fa
Slide 8: Free Cash Flow TTM
Free Cash Flow 8 TTM For the quarter ended 3/31/26 3/31/26 12/31/25 9/30/25 6/30/25 Net cash provided by operating activities $ 57,133 $ 8,071 $ 18,441 $ 18,367 $ 12,254 Less: Purchase of property and equipment (31,214) (6,712) (8,737) (7,636) (8,129) Proceeds from sale of property and equipment 10,
Slide 9: 2026 Annual Guidance – Commentary
2026 Annual Guidance – Commentary 9 Core Metrics • Net revenue of $312 million to $320 million (narrowed and raised from $310 million to $320 million) • Adjusted EBITDA of $65 million to $69 million (reaffirmed) • Net capital expenditures of 9% to 10.5% of net revenue (updated from prior range of 10
Slide 10: Adjusted EBITDA
Adjusted EBITDA 10 (a) Represents non-cash, equity-based compensation expense associated with option and RSU awards. (b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. (c) Represents impairments o